3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Colorectal Neoplasms
9
Neoplasm Metastasis
4
Sarcoma
3
Pancreatic Neoplasms
3
Lymphoma, Non-Hodgkin
3
Glioma
3
Breast Neoplasms
3
Wilms Tumor
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Hematologic Neoplasms
2
Ependymoma
2
Colorectal Cancer Metastatic
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Xanthogranuloma, Juvenile
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Interventions
Radiotherapy
2
Polymerase Chain Reaction
2
Nicotine
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Counseling
2
Bupropion
2
trametinib
1
pembrolizumab
1
motexafin gadolinium
1
fluoromisonidazole
1
durvalumab
1
dabrafenib
1
cobimetinib
1
Zinc Oxide
1
Vemurafenib
1
Varenicline
1
Tobacco Use Cessation Devices
1
Taxes
1
Surgical Procedures, Operative
1
Sucralfate
1
Salts
1
Rubidium-82
1
Ritonavir
1
Radiotherapy, Intensity-Modulated
1
Quality of Life
1
Psychiatric Rehabilitation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
Gastrointestinal
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled